1
|
Cao JY, Ning XP, Zhou GW, Li BL, Qiao F, Han L, Xu ZY, Lu FL. Pulmonary and tricuspid regurgitation after Tetralogy of Fallot repair: A case report. World J Cardiol 2023; 15:642-648. [PMID: 38173903 PMCID: PMC10758604 DOI: 10.4330/wjc.v15.i12.642] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/01/2023] [Revised: 11/13/2023] [Accepted: 12/11/2023] [Indexed: 12/25/2023] Open
Abstract
BACKGROUND Tetralogy of Fallot (TOF) is one of the most common congenital heart defects, and surgery is the primary treatment. There are no precise guidelines on the treatment protocol for tricuspid regurgitation (TR) as a common complication of TOF repair. The timing for treatment in patients presenting with valve regurgitation after TOF repair is often difficult to determine. Here, we report the first case of sequential treatment of pulmonary and TR using interventional therapy. CASE SUMMARY We present the case of a 52-year-old female patient, who had a history of TOF repair at a young age. A few years later, the patient presented with pulmonary and tricuspid regurgitation. The symptoms persisted and TR worsened following percutaneous pulmonary valve implantation. Preoperative testing revealed that the patient's disease had advanced to an intermediate to advanced stage and that her general health was precarious. Because open-heart surgery was not an option for the patient, transcatheter tricuspid valve replacement was suggested. This procedure was successful, and the patient recovered fully without any adverse effects. This case report may serve as a useful resource for planning future treatments. CONCLUSION Treatment of both valves should be considered in patients with tricuspid and pulmonary regurgitations following TOF repair. The interventional strategy could be an alternative for patients with poor general health.
Collapse
Affiliation(s)
- Jing-Yi Cao
- Department of Cardiovascular Surgery, Changhai Hospital, Shanghai 200433, China
| | - Xiao-Ping Ning
- Department of Cardiovascular Surgery, Changhai Hospital, Shanghai 200433, China
| | - Guang-Wei Zhou
- Department of Cardiovascular Surgery, Changhai Hospital, Shanghai 200433, China
| | - Bai-Ling Li
- Department of Cardiovascular Surgery, Changhai Hospital, Shanghai 200433, China
| | - Fan Qiao
- Department of Cardiovascular Surgery, Changhai Hospital, Shanghai 200433, China
| | - Lin Han
- Department of Cardiovascular Surgery, Changhai Hospital, Shanghai 200433, China
| | - Zhi-Yun Xu
- Department of Cardiovascular Surgery, Changhai Hospital, Shanghai 200433, China
| | - Fang-Lin Lu
- Department of Cardiovascular Surgery, Changhai Hospital, Shanghai 200433, China
- Department of Cardiovascular Surgery, Shanghai General Hospital, Shanghai 200080, China.
| |
Collapse
|
2
|
Ning XP, An Z, Qiao F, Cai CL, Han L, Song ZG, Li BL, Zhou GW, Wang J, Xu ZY, Lu FL. [Safety and efficacy of transcatheter tricuspid valve replacement with LuX-Valve in patients with severe tricuspid regurgitation]. Zhonghua Xin Xue Guan Bing Za Zhi 2021; 49:455-460. [PMID: 34034378 DOI: 10.3760/cma.j.cn112148-20210125-00091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objectives: To evaluate the safety and efficacy of LuX-Valve on the treatment of severe tricuspid regurgitation (TR). Methods: This is a prospective observational study. From September 2018 to March 2019, 12 patients with severe TR, who were not suitable for surgery, received LuX-Valve implantation in Changhai Hospital. LuX-Valve was implanted under general anesthesia and the guidance of transesophageal echocardiography and X-ray fluoroscopy. Access to the tricuspid valve was achieved via a minimally invasive thoracotomy and transatrial approach. Main endpoints were surgery success and device success. Surgery success was defined as successful implanting the device and withdrawing the delivery system, positioning the valve correctly and stably without severe or life-threatening adverse events. Device success was defined as satisfied valve function (TR severity reduction ≥ 2 grades, tricuspid gradient ≤ 6 mmHg (1 mmHg=0.133 kPa)), absence of malposition, valve failure and reintervention, major adverse events including device related mortality, embolization, conduction system disturbances and new onset shunt across ventricular septum at day 30 post implantation. Results: A total of 12 patients with severe to torrential TR were included in this study. The age was (68.5±6.9) years and 7 were female. All patients had typical right heart failure symptoms. Procedural success was achieved in all cases, there was no intraprocedural mortality or transfer to open surgery. TR significantly improved after LuX-Valve implantation (none/trivial in 8 patients, mild in 3 patients and moderate in 1 patient). The average device time was (9.2±4.2) minutes. Intensive care unit duration was 3.0 (2.0, 4.8) days. One patient died at postoperative day 18 due to non-surgery and device reasons. Transthoracic echocardiography at 30 days after operation showed that TR was significantly reduced (none/trivial in 8 patients, mild in 2 patients and moderate in 1 patient) and device success was achieved in 11 cases. All survived patients experienced a significant improvement in life quality with significantly improvement in New York Heart Association (NYHA) classification (Ⅰ and Ⅱ: 6/11 post operation vs. 0/11 before operation, P=0.012) and there were no device related complications in this patient cohort. Conclusions: LuX-Valve implantation is feasible, safe and effective for the treatment of patients with severe TR.
Collapse
Affiliation(s)
- X P Ning
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| | - Z An
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| | - F Qiao
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| | - C L Cai
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| | - L Han
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| | - Z G Song
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| | - B L Li
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| | - G W Zhou
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| | - J Wang
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| | - Z Y Xu
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| | - F L Lu
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| |
Collapse
|
3
|
Carrera A, Moos J, Ning XP, Gerton GL, Tesarik J, Kopf GS, Moss SB. Regulation of protein tyrosine phosphorylation in human sperm by a calcium/calmodulin-dependent mechanism: identification of A kinase anchor proteins as major substrates for tyrosine phosphorylation. Dev Biol 1996; 180:284-96. [PMID: 8948591 DOI: 10.1006/dbio.1996.0301] [Citation(s) in RCA: 238] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Signal transduction pathways regulate various aspects of mammalian sperm function. When human sperm were incubated in a medium supporting capacitation, proteins became tyrosine-phosphorylated in a time-dependent manner. This phosphorylation was inhibited by genistein, a protein tyrosine kinase inhibitor. Phosphorylation was also reduced when sperm were incubated either in the presence of increasing concentrations of extracellular Ca2+ or in a medium containing the Ca2+ ionophore A23187. This Ca2+-induced dephosphorylation was calmodulin-dependent, suggesting that calcineurin was involved. In this regard, the calcineurin inhibitor deltamethrin inhibited the Ca2+ ionophore-induced dephosphorylation. A limited number of Mr 80,000-105,000 polypeptides were the most prominent phosphotyrosine-containing proteins present in human sperm. Unlike mouse sperm, which contains a tyrosine-phosphorylated isoform of hexokinase, a phosphotyrosine-containing hexokinase in human sperm was not detected. Most of the tyrosine-phosphorylated proteins were Triton X-100-insoluble and were localized to the principal piece of the flagellum, the region where the cytoskeletal fibrous sheath is found. Prominent phosphotyrosine-containing proteins of Mr 82,000 and 97,000 were identified as the human homologues of mouse sperm AKAP82, the major fibrous sheath protein, and pro-AKAP82, its precursor polypeptide, respectively. These proteins are A Kinase Anchor Proteins, polypeptides that sequester protein kinase A to subcellular locations. Taken together, these results suggest that protein tyrosine phosphorylation may be part of a signal transduction cascade(s) regulating events pertaining to capacitation and/or motility in mammalian sperm and that an interrelationship between tyrosine kinase and cAMP signaling pathways exists in these cells.
Collapse
Affiliation(s)
- A Carrera
- Department of Obstetrics and Gynecology, University of Pennsylvania Medical Center, Philadelphia 19104-6080, USA
| | | | | | | | | | | | | |
Collapse
|